CVRx, a company focused on heart health solutions, announced that Humana will cover its Barostim therapy for heart failure patients starting May 1, 2026. This coverage is significant because Humana is one of the largest Medicare Advantage providers in the U.S., serving around 5.2 million members. Barostim is an innovative implantable device that uses electrical pulses to help manage heart failure symptoms by restoring balance in the nervous system.

For people living with heart failure, this development could mean better access to a therapy that may improve their quality of life. Barostim is designed for patients who meet specific FDA-approved criteria, and those enrolled in the ongoing BENEFIT-HF trial, which is studying its effects in a broader population. With this coverage, more patients may benefit from a treatment that has been recognized for its potential to alleviate the burdens of heart failure.

The announcement follows other positive steps for Barostim, including the introduction of new billing codes and Medicare coverage for trial participants earlier this year. While Barostim has received FDA Breakthrough Device designation and is approved for use in the U.S., it is still essential to recognize that the therapy’s long-term effectiveness is being actively studied.

As this therapy becomes more widely accessible through insurance coverage, individuals with heart failure might consider discussing Barostim with their healthcare providers to see if it could be a suitable option for them.

Source: globenewswire.com